---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-22-000027"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T20:34:18.130560+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen Q1 revenue $10.4M, net loss widens to $10.3M; raises FY 2022 guidance

## Summary
- Q1 testing revenue $10.4M (flat YoY); total revenue $10.4M vs $10.6M in Q1 2021.
- Net loss $10.3M ($0.84 loss per share) vs $6.2M loss a year ago; gross margin fell to 44% from 55.5%.
- AVISE CTD test volume 30,903 (+6.5% YoY); record 2,175 ordering healthcare providers and 761 adopters.
- FY 2022 revenue guidance raised to $53-55M from $51-53M; cash $89.8M at quarter end.
- AMA issued PLA code for AVISE Lupus; Centene/WellCare in-network effective June 1, 2022.

## SEC filing metadata
- accession: 0001274737-22-000027
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/0001274737-22-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/exdx-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-22-000027
- JSON: https://secwatch.observer/filing/0001274737-22-000027.json
- Plain text: https://secwatch.observer/filing/0001274737-22-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.